Lipoprotein-insulin resistance score is associated with atherosclerotic cardiovascular disease in liver transplant recipients.
文献摘要
Background Liver transplant (LT) recipients have increased atherogenic risk, which is difficult to quantify via available diagnostic tests. Objective The aim of the present study was to evaluate the diagnostic performance of the lipoprotein insulin resistance index (LP-IR) score, a composite biomarker of insulin resistance and metabolic risk, and its association with atherosclerotic cardiovascular disease (ASCVD) in LT recipients. Methods Analysis was performed in 218 LT recipients who were enrolled in a natural history study. Blood samples were collected after an overnight fast, and LP-IR was analyzed via nuclear magnetic resonance. The primary outcome was a composite endpoint consisting of new-onset coronary artery disease, nonfatal myocardial infarction, stroke, or sudden cardiac death. Cox regression models were constructed and adjusted to traditional ASCVD risk factors, liver disease, and immunosuppression. Results ASCVD was present in 47 LT recipients after a median follow-up of 47 months after study enrollment. In the adjusted analysis, LP-IR was significantly associated with future risk of the primary outcome, with a hazard ratio of 1.024 (95% CI 1.009 and 1.039, P = .002) that was independent of conventional risk factors. Combining LP-IR with diabetes improved the performance compared to either parameter alone. LP-IR had a higher diagnostic performance compared to the conventional lipid profile (low-density lipoprotein cholesterol, high-density lipoprotein cholesterol, total cholesterol) and hepatic panel in predicting future risk of ASCVD. Conclusion LP-IR is associated with future risk of ASCVD in LT recipients with or without diabetes and may have utility as a prognostic biomarker; however, study findings require development of a risk model and further validation.